Knockdown of mTOR by lentivirus-mediated RNA interference suppresses atherosclerosis and stabilizes plaques via a decrease of macrophages by autophagy in apolipoprotein E-deficient mice

International Journal of Molecular Medicine

Volumn 32, Issue 5, 2013, Pages 1215-1221

  Wang, Xiaochuang ^a   Li, Lingxia ^a   Li, Manxiang ^a   Dang, Xiaoyan ^a   Wan, Lin ^a   Wang, Ni ^a   Bi, Xiaoju ^a   Gu, Changwei ^a   Qiu, Suijuan ^a   Niu, Xiaolin ^a   Zhu, Xinye ^a   Wang, Lina ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Atherosclerotic plaque; Autophagy; Macrophage; Mammalian target of rapamycin; Small hairpin RNA

Indexed keywords

APOLIPOPROTEIN E; CHOLESTEROL; GELATINASE A; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LENTIVIRUS VECTOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MAMMALIAN TARGET OF RAPAMYCIN; MONOCYTE CHEMOTACTIC PROTEIN 1; SHORT HAIRPIN RNA; THROMBOPLASTIN; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; AUTOPHAGY; CAROTID ARTERY; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; DEPHOSPHORYLATION; DISEASE COURSE; GENE SILENCING; GENETIC TRANSFECTION; LIPID DIET; LIPID METABOLISM; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TRIACYLGLYCEROL BLOOD LEVEL; WESTERN BLOTTING;

ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; AUTOPHAGY; LENTIVIRUS; MACROPHAGES; MALE; MICE; MICE, MUTANT STRAINS; RNA INTERFERENCE; TOR SERINE-THREONINE KINASES;

EID: 84885085833     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2013.1494     Document Type: Article

References (48)

1. Davies MJ and Thomas AC: Plaque fissuring - the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. Br Heart J 53: 363-373, 1985.
2. Falk E, Shah PK and Fuster V: Coronary plaque disruption. Circulation 92: 657-671, 1995
3. Davies MJ, Richardson PD, Woolf N, Katz DR and Mann J: Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J 69: 377-381, 1993.
4. Virmani R, Burke AP, Farb A and Kolodgie FD: Pathology of the vulnerable plaque. J Am Coll Cardiol 47 C13-C18, 2006.
5. Mizuno Y, Jacob RF and Mason R: Inflammation and the development of atherosclerosis. J Atheroscler Thromb 18: 351-358, 2 011.
6. Libby P, Ridker PM and Maseri A: Inflammation and atherosclerosis. Circulation 105: 1135-1143, 2002.
7. Shah PK, Falk E, Badimon J.J., et al.: Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metal-loproteinases and implications for plaque rupture. Circulation 92: 1565-1569, 1995.
8. Niu J and Kolattukudy PE: Role of MCP-1 in cardiovascular disease: molecular mechanisms and clinical implications. Clin Sci (Lond) 117: 95-109, 2009.
9. Lwaleed BA, Cooper AJ, Voegeli D and Getliffe K: Tissue factor: a critical role in inflammation and cancer. Biol Res Nurs 9: 97-107, 2007.
10. Boyle JJ: Macrophage activation in atherosclerosis: pathogenesis and pharmacology of plaque rupture. Curr Vasc Pharmacol 3: 63-68, 20 05.
11. Verheye S, Martinet W, Kockx M.M., et al.: Selective clearance of macrophages in atherosclerotic plaques by autophagy. J Am Coll Cardiol 49: 706-715, 2007.
12. Thomas G and Hall MN: TOR signalling and control of cell growth. Curr Opin Cell Biol 9: 782-787, 1997.
13. Dennis PB, Fumagalli S and Thomas G: Target of rapamycin (TOR): balancing the opposing forces of protein synthesis and degradation. Curr Opin Genet Dev 9: 49-54, 1999.
14. Easton JB and Houghton PJ: Therapeutic potential of target of rapamycin inhibitors. Expert Opin Ther Targets 8: 551-564, 2004.
15. Woltman AM, van der Kooij SW, Coffer PJ, et al.: Rapamycin specifically interferes with GM-CSF signaling in human dendritic cells, leading to apoptosis via increased p27KIP1 expression. Blood 101: 1439-1445, 2003.
16. Huang S, Shu L, Dilling M.B., et al.: Sustained activation of the JNK cascade and rapamycin-induced apoptosis are suppressed by p53/p21(Cip1). Mol Cell 11: 1491-1501, 2003.
17. Ravikumar B, Vacher C, Berger Z., et al.: Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet 36: 585-595, 2004.
18. Noda T and Ohsumi Y: Tor, a phosphatidylinositol kinase homologue, controls autophagy in yeast. J Biol Chem 273: 3963-3966, 1998.
19. Abraham RT and Gibbons JJ: The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy. Clin Cancer Res 13: 3109-3114, 2007.
20. Suzuki T, Kopia G, Hayashi S., et al.: Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation 104: 1188-1193, 2001.
21. Elloso MM, Azrolan N, Sehgal S.N., et al.: Protective effect of the immunosuppressant sirolimus against aortic atherosclerosis in apo E-deficient mice. Am J Transplant 3: 562-569, 2003.
22. Mizushima N and Komatsu M: Autophagy: renovation of cells and tissues. Cell 147: 728-741, 2011.
23. Yang Z and Klionsky DJ: Eaten alive: a history of macroau-tophagy. Nat Cell Biol 12: 814-822, 2010.
24. Chen Y, Lin MC, Yao H, et al.: Lentivirus-mediated RNA interference targeting enhancer of zeste homolog 2 inhibits hepatocellular carcinoma growth through down-regulation of stathmin. Hepatology 46: 200-208, 2007.
25. Jiang L, Lai YK, Zhang J, et al.: Targeting S100P inhibits colon cancer growth and metastasis by lentivirus-mediated RNA interference and proteomic analysis. Mol Med 17: 709-716, 2011.
26. von der Thusen JH, van Berkel TJ and Biessen EA: Induction of rapid atherogenesis by perivascular carotid collar placement in apolipoprotein E-deficient and low-density lipoprotein receptor-deficient mice. Circulation 103: 1164-1170, 2001.
27. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2-(Delta Delta C(T)) method. Methods 25: 402-408, 2001.
28. Levine B and Klionsky DJ: Development by self-digestion: molecular mechanisms and biological functions of autophagy. Dev Cell 6: 463-477, 2004.
29. Mizushima N: Methods for monitoring autophagy. Int J Biochem Cell Biol 36: 2491-2502, 2004.
30. Toth PP: High-density lipoprotein as a therapeutic target: clinical evidence and treatment strategies. Am J Cardiol 96: 50K-58K, 20 05.
31. Ma KL, Ruan XZ, Powis S.H., Moorhead JF and Varghese Z: Anti-atherosclerotic effects of sirolimus on human vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 292: H2721-H2728, 2007.
32. Ma KL, Varghese Z, Ku Y., et al.: Sirolimus inhibits endogenous cholesterol synthesis induced by inflammatory stress in human vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 2 9 8: H16 4 6 - H16 51, 2 010.
33. Mathis AS, Jin S, Friedman G.S., et al.: The pharmacodynamic effects of sirolimus and sirolimus-calcineurin inhibitor combinations on macrophage scavenger and nuclear hormone receptors. J Pharm Sci 96: 209-222, 2007.
34. Croons V, Martinet W, Herman A.G., Timmermans JP and De Meyer GR: Selective clearance of macrophages in atherosclerotic plaques by the protein synthesis inhibitor cycloheximide. J Pharmacol Exp Ther 320: 986-993, 2007.
35. Martinet W, Verheye S, De Meyer I, et al.: Everolimus triggers cytokine release by macrophages: rationale for stents eluting everolimus and a glucocorticoid. Arterioscler Thromb Vasc Biol 32: 1228-1235, 2012.
36. Huang WP, Scott SV, Kim J and Klionsky DJ: The itinerary of a vesicle component, Aut7p/Cvt5p, terminates in the yeast vacuole via the autophagy/Cvt pathways. J Biol Chem 275: 5845-5851, 2000.
37. Chan TF, Bertram PG, Ai W and Zheng XF: Regulation of APG14 expression by the GATA-type transcription factor Gln3p. J Biol Chem 276: 6463-6467, 2001.
38. Crouzet J, Faucher JF, Toubin M, Hoen B and Estavoyer JM: Serum C-reactive protein (CRP) and procalcitonin (PCT) levels and kinetics in patients with leptospirosis. Eur J Clin Microbiol Infect Dis 30: 299-302, 2011.
39. Bea F, Blessing E, Bennett B., et al.: Simvastatin promotes atherosclerotic plaque stability in apoE-deficient mice independently of lipid lowering. Arterioscler Thromb Vasc Biol 22: 1832-1837, 2002.
40. Zaman AG, Helft G, Worthley SG and Badimon JJ: The role of plaque rupture and thrombosis in coronary artery disease. Atherosclerosis 149: 251-266, 2000.
41. Morancho A, Rosell A, García-Bonilla L and Montaner J: Metalloproteinase and stroke infarct size: role for anti-inflamma-tory treatment? Ann NY Acad Sci 1207: 123-133, 2010.
42. Deshmane SL, Kremlev S, Amini S and Sawaya BE: Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res 29: 313-326, 2009.
43. Rull A, Beltrán-Debón R, Aragonès G, et al.: Expression of cytokine genes in the aorta is altered by the deficiency in MCP-1: effect of a high-fat, high-cholesterol diet. Cytokine 50: 121-128, 2010.
44. Liu XL, Zhang PF, Ding S.F., et al.: Local gene silencing of monocyte chemoattractant protein-1 prevents vulnerable plaque disruption in apolipoprotein E-knockout mice. PLoS One 7: e33 49 7, 2 012.
45. Jude B, Zawadzki C, Susen S and Corseaux D: Relevance of tissue factor in cardiovascular disease. Arch Mal Coeur Vaiss 98: 667-671, 2005.
46. Kume N: Molecular mechanisms of coronary atherosclerotic plaque formation and rupture. Nihon Rinsho 68: 637-641, 2010 (In Japanese).
47. Song E, Lee SK, Wang J, et al.: RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med 9: 347-351, 20 03.
48. Paroo Z and Corey DR: Challenges for RNAi in vivo. Trends Biotechnol 22: 390-394, 2004.